# Croda International Plc Q1 sales up 8%, outlook unchanged

- Link: https://www.directorstalkinterviews.com/croda-international-plc-q1-sales-up-8-outlook-unchanged/4121193369
- Published: 2025-04-23T07:40:45+01:00
- Author: Amilia Stone

**[Croda International Plc](https://www.directorstalkinterviews.com/ftse-company/croda-international/crdo.l)**(
LON:CRDA) has provided an update on its sales performance in the first quarter of
2025 (the three months ended 31 March 2025).

·      Group sales of £442m, up 8% versus the prior year and up 9% at constant currency

·      Life Sciences, Consumer Care and Industrial Specialities all delivered good
sales growth

·      Good progress delivering our five-point plan to drive sales growth and margin
recovery

·      Q1 profit before tax in line with expectations

**Group performance**

|  |  | **                                 Change versus prior year** | 
|  | Q125£m | Q124£m | Change | Constant currency change | 
| Consumer Care | **255** | 237 | 8% | 8% | 
| Life Sciences | **134** | 122 | 10% | 11% | 
| Industrial Specialties | **53** | 50 | 6% | 7% | 
| Group | **442** | **409** | **8%** | **9%** |

First quarter sales increased to £442m, up 8% on a reported basis on the prior year
and up 9% in constant currency. Good sales growth was driven by higher sales volumes
with the price/mix headwinds we saw in 2024 starting to diminish. Overall, Group
adjusted profit before tax in the first quarter was in line with our expectations.

With higher sales volumes in the first quarter, asset utilisation at our 11 shared
manufacturing sites has continued to improve. We have continued to successfully 
implement our plan to realise £25m of cost savings this year whilst identifying 
further opportunities to deliver operational efficiencies as part of our multi-year
programme.  

Overall, we are making good progress delivering the five priorities outlined in 
February to improve our financial performance. These are to grow sales by:

·      Leveraging our proximity to customers

·      Converting our innovation pipelines

·      Driving value from recent investments

and to drive margin recovery by:

·      Increasing sales volumes to enhance utilisation rates

·      Realigning our cost base

As widely reported, the recent introduction of trade tariffs and increased geopolitical
tensions have made the global economic outlook more uncertain. Although our well-
balanced local manufacturing and procurement model helps to mitigate our direct 
exposure to tariffs, we are assessing the likely impact, talking to our customers
and intend to apply a tariff surcharge to cover any associated incremental costs.

Whilst we recognise that the political and economic environment has become less 
predictable, the Group’s encouraging start to the year means that our Full Year 
2025 outlook is unchanged. As things stand, we continue to expect to deliver £265m
to £295m Group adjusted profit before tax at constant currency.

**Regional performance**

| **% change in sales versus the prior year** | Change | Constant currency change | 
| EMEA | 11% | 13% | 
| North America | 4% | 4% | 
| Latin America | 6% | 5% | 
| Asia | 8% | 9% | 
| **Group** | **8%** | **9%** |

All regions delivered good sales growth, with EMEA particularly strong.

**Business performance**

**Consumer Care**

| **% change in sales versus the prior year** | Change | Constant currency change | 
| Beauty Actives | (2)% | (1)% | 
| Beauty Care | 5% | 6% | 
| F&F | 19% | 19% | 
| Home Care | 5% | 5% | 
| **Total Consumer Care** | **8%** | **8%** |

Sales in Consumer Care were up 8% both on a reported and constant currency basis,
driven by higher sales volumes and continued strong demand from local customers.
Fragrances & Flavours continued to deliver strong sales growth. Beauty Care and 
Home Care delivered mid-single digit percentage sales growth driven by higher sales
volumes. Year-on-year sales were down slightly in Beauty Actives against a good 
comparator period but were up strongly on a sequential basis compared with the final
quarter of 2024.   

**Life Sciences**

| **% change in sales versus the prior year** | Change | Constant currency change | 
| Pharma | 6% | 7% | 
| Crop Protection | 17% | 18% | 
| Seed Enhancement | 14% | 15% | 
| **Total Life Sciences** | **10%** | **11%** |

Reported sales in Life Sciences were up 10%, or by 11% at constant currency. Crop
Protection and Seed Enhancement both delivered strong sales growth. Pharma sales
were also higher, both on a year-on-year and a sequential business, with growth 
in our strategic focus areas in biopharma more than offsetting continued challenges
in consumer health and veterinary markets.

**Industrial Specialties**

Reported sales in Industrial Specialties grew by 6%, or by 7% at constant currency,
again driven by higher sales volumes.

**Quarterly sales performance**

| **Quarterly sales****£m** | ConsumerCare | LifeSciences | IndustrialSpecialties | Group | 
| Q1 2024 | 236.8 | 121.8 | 49.9 | 408.5 | 
| Q2 2024 | 231.6 | 124.4 | 51.4 | 407.4 | 
| Q3 2024 | 228.1 | 128.8 | 49.7 | 406.6 | 
| Q4 2024 | 223.5 | 129.3 | 52.8 | 405.6 | 
| Q1 2025 | 255.1 | 134.5 | 52.7 | 442.3 | 
| **Half** **yearly sales £m** | ConsumerCare | LifeSciences | IndustrialSpecialties | Group | 
| H1 2024 | 468.4 | 246.2 | 101.3 | 815.9 | 
| H2 2024 | 451.6 | 258.1 | 102.5 | 812.2 |

**Further information**

Croda is hosting a conference call for analysts and investors at 7.30am BST this
morning. Please register in advance at: www.croda.com/investors.

Our Annual General Meeting (AGM) is taking place at 12 noon today at The Milner 
York, Station Road, York, England, YO24 1AA.

Croda will report half year 2025 results on 29 July 2025.

#  

Share on:
